Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer.
D. Thaper, R. Munuganti, A. Aguda, S. Kim, S.-y. Ku, O. Sivak, S. Kumar, S. Vahid, D. Ganguli, H. Beltran, C. M. Morrissey, E. Corey, A. Zoubeidi
This paper develops and characterizes B18-94, the first BRN2 inhibitor, showing efficacy in reducing NEPC tumor growth with no toxicity.
bioRxiv · May 4, 2022 · PreprintCancer Biology